Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 271

The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.

Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma

Open access
Haradhvala, Nicholas J., Leick, Mark B., Maurer, Katie, Gohil, Satyen H., Larson, Rebecca C., Yao, Ning, Gallagher, Kathleen M. E., Katsis, Katelin, Frigault, Matthew J., Southard, Jackson, Li, Shuqiang, Kann, Michael C., Silva, Harrison, Jan, Max, Rhrissorrakrai, Kahn, Utro, Filippo, Levovitz, Chaya, Jacobs, Raquel A., Slowik, Kara, Danysh, Brian P., Livak, Kenneth J., Parida, Laxmi, Ferry, Judith, Jacobson, Caron, Wu, Catherine J., Getz, Gad, Maus, Marcela V. · 2022 · Nature Medicine

Abstract

Chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of hematologic malignancies. Approximately half of patients with refractory large B cell lymphomas achieve durable responses from CD19-targeting CAR-T treatment; however, failure mechanisms are identified in only a fraction of cases. To gain new insights into the basis of clinical response, we performed single-cell transcriptome sequencing of 105 pretreatment and post-treatment peripheral blood mononuclear cell samples, and infusion products collected from 32 individuals with large B cell lymphoma treated with either of two CD19 CAR-T products: axicabtagene ciloleucel (axi-cel) or tisagenlecleucel (tisa-cel). Expansion of proliferative memory-like CD8 clones was a hallmark of tisa-cel response, whereas axi-cel responders displayed more heterogeneous populations. Elevations in CAR-T regulatory cells among nonresponders to axi-cel were detected, and these populations were capable of suppressing conventional CAR-T cell expansion and driving late relapses in an in vivo model. Our analyses reveal the temporal dynamics of effective responses to CAR-T therapy, the distinct molecular phenotypes of CAR-T cells with differing designs, and the capacity for even small increases in CAR-T regulatory cells to drive relapse. Single-cell transcriptomics analyses of pretreatment and post-treatment peripheral blood mononuclear cells from patients treated with CD19 chimeric antigen receptor (CAR)-T products reveal a role for CAR-T regulatory cells in treatment relapse.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-022-01959-0

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 59 references

Cited by

See all 271

Metadata

Authors
Haradhvala, N. J., Leick, M. B., Maurer, K., Gohil, S. H., Larson, R. C., Yao, N., Gallagher, K. M. E., Katsis, K., Frigault, M. J., Southard, J., Li, S., Kann, M. C., Silva, H., Jan, M., Rhrissorrakrai, K., Utro, F., Levovitz, C., Jacobs, R. A., Slowik, K., Danysh, B. P., Livak, K. J., Parida, L., Ferry, J., Jacobson, C., Wu, C. J., Getz, G., & Maus, M. V.
Venue
Nature Medicine
Published
2022-09
Volume
28
Issue
9
Pages
1848-1859
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4295454080
Cited by
271
References
59
FWCI
19.94
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma. https://app.cochat.ai/papers/10.1038/s41591-022-01959-0
The paper
Haradhvala, N. J., Leick, M. B., Maurer, K., Gohil, S. H., Larson, R. C., Yao, N., Gallagher, K. M. E., Katsis, K., Frigault, M. J., Southard, J., Li, S., Kann, M. C., Silva, H., Jan, M., Rhrissorrakrai, K., Utro, F., Levovitz, C., Jacobs, R. A., Slowik, K., . . . Maus, M. V. (2022). Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma. Nature Medicine. https://doi.org/10.1038/s41591-022-01959-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.